IRIS
BARILLARI, GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 30.703
AS - Asia 3.032
EU - Europa 2.760
SA - Sud America 449
Continente sconosciuto - Info sul continente non disponibili 380
AF - Africa 43
OC - Oceania 6
Totale 37.373
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 30.544
SG - Singapore 1.522
CN - Cina 632
IT - Italia 517
DE - Germania 474
UA - Ucraina 398
BR - Brasile 361
RU - Federazione Russa 361
IE - Irlanda 287
HK - Hong Kong 240
VN - Vietnam 221
FR - Francia 185
GB - Regno Unito 152
PL - Polonia 111
BD - Bangladesh 94
JP - Giappone 93
CA - Canada 85
FI - Finlandia 75
SE - Svezia 52
NL - Olanda 47
IN - India 44
KR - Corea 36
ID - Indonesia 34
AR - Argentina 27
MX - Messico 23
ES - Italia 20
TW - Taiwan 19
AT - Austria 18
TR - Turchia 18
IQ - Iraq 16
ZA - Sudafrica 16
EC - Ecuador 15
CO - Colombia 14
BE - Belgio 12
CR - Costa Rica 10
JM - Giamaica 10
PH - Filippine 10
CZ - Repubblica Ceca 9
VE - Venezuela 9
CL - Cile 8
PK - Pakistan 8
AL - Albania 7
AU - Australia 6
TH - Thailandia 6
DK - Danimarca 5
EG - Egitto 5
GT - Guatemala 5
MA - Marocco 5
TT - Trinidad e Tobago 5
UZ - Uzbekistan 5
HN - Honduras 4
KE - Kenya 4
LT - Lituania 4
MY - Malesia 4
PE - Perù 4
PR - Porto Rico 4
SA - Arabia Saudita 4
BB - Barbados 3
BO - Bolivia 3
BS - Bahamas 3
CH - Svizzera 3
CI - Costa d'Avorio 3
DZ - Algeria 3
EE - Estonia 3
EU - Europa 3
JO - Giordania 3
KZ - Kazakistan 3
LB - Libano 3
NG - Nigeria 3
PY - Paraguay 3
RO - Romania 3
SV - El Salvador 3
UY - Uruguay 3
AE - Emirati Arabi Uniti 2
BG - Bulgaria 2
BY - Bielorussia 2
DO - Repubblica Dominicana 2
GR - Grecia 2
HU - Ungheria 2
LV - Lettonia 2
NP - Nepal 2
QA - Qatar 2
RS - Serbia 2
TN - Tunisia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
AZ - Azerbaigian 1
BZ - Belize 1
FK - Isole Falkland (Malvinas) 1
GE - Georgia 1
GY - Guiana 1
HR - Croazia 1
IL - Israele 1
IR - Iran 1
KG - Kirghizistan 1
KW - Kuwait 1
LK - Sri Lanka 1
LU - Lussemburgo 1
LY - Libia 1
MD - Moldavia 1
Totale 36.990
Salva come PNG Salva come JPEG
Città #
Wilmington 7.707
Woodbridge 7.444
Houston 6.820
Singapore 908
Ashburn 814
Fairfield 619
Chandler 577
San Jose 512
Ann Arbor 391
Dearborn 318
Dublin 267
Seattle 233
Hong Kong 232
New York 218
Council Bluffs 213
Jacksonville 211
Cambridge 210
Medford 200
Beijing 198
Santa Clara 173
Rome 170
Los Angeles 167
Chicago 122
Buffalo 103
The Dalles 94
Lawrence 93
Kraków 88
Dallas 77
Tokyo 74
Menlo Park 70
Zhengzhou 70
Ho Chi Minh City 67
Lauterbourg 66
Hanoi 59
San Diego 55
Moscow 52
Salt Lake City 50
São Paulo 44
Denver 37
Milan 36
Phoenix 36
Helsinki 35
Boardman 30
Atlanta 28
Nuremberg 27
Frankfurt am Main 26
Redondo Beach 25
Tampa 25
Jakarta 22
Toronto 20
Warsaw 20
Elk Grove Village 19
Mülheim 19
Orem 19
Chennai 18
Guangzhou 18
Redwood City 17
London 16
Montreal 16
Nanjing 16
Norwalk 16
Brooklyn 15
Shanghai 15
Lappeenranta 14
Miami 13
San Francisco 13
Verona 13
Boston 12
Brussels 12
Columbus 12
Detroit 12
Dulles 12
Manchester 12
Mountain View 12
Naples 12
Philadelphia 12
Washington 12
Las Vegas 11
Munich 11
Sterling 11
Stockholm 11
Charlotte 10
Riverside 10
Amsterdam 9
Brasília 9
Center 9
Johannesburg 9
Pittsburgh 9
Rio de Janeiro 9
Baghdad 8
Colorado Springs 8
Da Nang 8
Haiphong 8
Kaohsiung 8
Lancaster 8
Poplar 8
San José 8
Wuhan 8
Belo Horizonte 7
Cincinnati 7
Totale 30.734
Salva come PNG Salva come JPEG
Nome #
Angiogenic effects of extracellular human immunodeficiency virus type 1 Tat protein and its role in the pathogenesis of AIDS-associated Kaposi's sarcoma 1.038
Detection of high nerve growth factor serum levels in AIDS-related and -unrelated Kaposi's sarcoma patients 549
Correlation between pathological data and the RNA expression of p53 or p53-targeted genes in primary invasive ductal breast carcinomas: a preliminary study 509
HTLV-V: a new human retrovirus isolated in a Tac-negative T cell lymphoma/leukemia 496
Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responses 495
Ritonavir or saquinavir impairs the invasion of cervical intraepithelial neoplasia cells via a reduction of MMP expression and activity. 475
The basic residues of placenta growth factor type 2 retrieve sequestered angiogenic factors into a soluble form: implications for tumor angiogenesis 469
Fibroblast growth factor-2 transiently activates the p53 oncosuppressor protein in human primary vascular smooth muscle cells: implications for atherogenesis 466
HIV-1 Tat regulates endothelial cell cycle progression via activation of the Ras/ERK MAPK signaling pathway 462
A tricistronic retroviral vector expressing natural antiangiogenic factors inhibits angiogenesis in vitro, but is not able to block tumor progression in vivo 452
Human T-lymphotropic retrovirus infection in Italy 450
Immobilized HIV-1 Tat protein promotes gene transfer via a transactivation independent mechanism which requires binding of Tat to viral particles 450
The HIV protease inhibitor indinavir down-regulates the expression of the pro-angiogenic MT1-MMP by human endothelial cells 449
Antitumor effects of antiretroviral therapy 446
The fibroblast growth factors. 444
Fibroblast growth factor-2 and the HIV-1 Tat protein synergize in promoting Bcl-2 expression and preventing endothelial cell apoptosis: implications for the pathogenesis of AIDS-associated Kaposi’s sarcoma. 441
Inflammatory cytokines stimulate vascular smooth muscle cells locomotion and growth by enhancing alpha5beta1 integrin expression and function 437
Pharmacological management of Kaposi’s sarcoma. 437
Fibroblast growth factor-2 transiently activates the p53 oncosuppressor protein in human primary vascular smooth muscle cells: implications for atherogenesis. 433
Inhibition of MMP-9 expression by ritonavir or saquinavir is associated with inactivation of the AKT/Fra-1 pathway in cervical intraepithelial neoplasia cells 433
Block of AIDS-Kaposi's sarcoma (KS) cell growth, angiogenesis, and lesion formation in nude mice by antisense oligonucleotide targeting basic fibroblast growth factor. A novel strategy for the therapy of KS 429
Another mechanism involved in AIDS-KS progression. 428
Pathogenesis of AIDS-associated Kaposi's sarcoma 424
Spindle cells from Acquired Immune Deficiency Syndrome-associated Kaposi’s sarcoma lesions express telomerase activity directly relating to the RNA levels of fibroblast growth factor-2. 419
HIV-1 Tat addresses dendritic cells to induce a predominant Th1-type adaptive immune response that appears prevalent in the asymptomatic stage of infection 418
Entrance of the tat protein of HIV-1 into human uterine cervical carcinoma cells causes upregulation of HPV-E6 expression and a decrease in p53 protein levels 415
Molecular mechanisms in the pathogenesis of AIDS-associated Kaposi's sarcoma 410
Angiogenic properties of human immunodeficiency virus type 1 Tat protein 408
Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth 404
HIV protease inhibitors as new treatment options for Kaposi's sarcoma 400
Treatment of Kaposi's sarcoma--an update 400
Follow-up study of patients with cervical intraepithelial neoplasia grade 1 overexpressing p16ink4a. 398
Basic fibroblast growth factor modifies the interactions between endothelial cells/fibronectin: Implications for progression of AIDS- associated Kaposi's sarcoma 397
Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients 396
HTLV-I and HIV infection in drug addicts in Italy 393
Transcription of placenta growth factor type-2 correlates with intratumoral microvessel density in breast carcinomas. 390
Human immunodeficiency virus protease inhibitors reduce the growth of human tumors via proteasome-independent block of angiogenesis and matrix metalloproteinases. 387
Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation 385
Activation of matrix-metalloproteinase-2 and membrane-type-1-matrix-metalloproteinase in endothelial cells and induction of vascular permeability in vivo by human immunodeficiency virus-1 Tat protein and basic fibroblast growth factor 385
The helical domain of GBP-1 mediates the inhibition of endothelial cell proliferation by inflammatory cytokines 385
The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence 384
Spindle cells from AIDS-associated Kaposi's sarcoma (KS) lesions express telomerase activity that is enhanced by KS progression factors. 379
Human T-lymphotropic retroviruses: a new member of the family. 379
Clinical course of classic Kaposi's sarcoma in HIV-negative patients treated with the HIV protease inhibitor indinavir 377
HTLV-I is endemic in southern Italy: detection of the first infectious cluster in a white population 375
Basic fibroblast growth factor mediates the growth and angiogenic activity of AIDS-Kaposi’s sarcoma (KS)-derived spindle cells and synergises with HIV-1 Tat protein in inducing KS-like lesions in mice. 373
HIV protease inhibitors block angiogenesis and promote regression of Kaposi’s sarcoma in the nude mouse model. 367
Tat, the transactivator gene of HIV-1, activates the expression of tumor necrosis factor-beta. 362
Release and angiogenic properties of extracellular HIV-1 Tat protein. 359
The use of HAART for biological tumour therapy 357
Lymphokines released by activated or HTLV-infected T cells induce growth of normal mesenchymal cells and of cells derived from Kaposi’s sarcoma lesions of AIDS patients. 357
Biology of Kaposi's sarcoma 354
Cytokines and growth factors in the pathogenesis of AIDS-associated Kaposi's sarcoma 352
Release-uptake of HIV-1 Tat and mechanisms of Tat-induced paracrine biological effects (TAT domains and pathways for cell growth and transactivation activity). 352
Integrin-mediated uptake of HIV-1 Tat protein by cytokine-activated endothelial cells. 350
Immobilized HIV-1 Tat protein promotes gene transfer via a transactivation independent mechanism which requires binding of Tat to viral particles. 348
Biological properties of Human Immunodeficiency Virus type-1 Tat protein: angiogenic effects and adhesive interactions of extracellular Tat. 347
Immune activation, rather than immune deficiency, cooperates with HIV infection in the development of AIDS-associated Kaposi’s sarcoma. 347
null 345
IFN-gamma induces endothelial cells to proliferate and to invade the extracellular matrix in response to the HIV-1 Tat protein: implications for AIDS-Kaposi's sarcoma pathogenesis 343
Role of HIV-1 TAT gene product and of cytokines released by activated immune cells in the pathogenesis of AIDS-associated Kaposi’s sarcoma. 341
The formation of new blood vessels in Kaposi’s sarcoma. 339
Multicistronic antiangiogenic retroviral vectors for the gene therapy of malignant brain tumors. 335
HIV-1 Tat protein mimics the effect of extracellular matrix (ECM) protein on vascular cell growth and angiogenesis: implications for AIDS-Kaposi’s sarcoma (AIDS-KS) pathogenesis. 335
Inflammatory cytokines synergize with the HIV-1 Tat protein to promote angiogenesis and Kaposi's sarcoma via induction of basic fibroblast growth factor and the alpha v beta 3 integrin 333
PDGF-B as a possible growth factor in AIDS-KS. 333
Interactions between endothelial cells and HIV-1 332
Mechanism of paclitaxel activity in Kaposi's sarcoma 331
Tissue CEA as prognostic indicator in a series of 31 cases of gastric cancer 331
HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma 331
HIV protease inhibitors: antiretroviral agents with anti-inflammatory, anti-angiogenic and anti-tumour activity 330
Basic FGF induces lesions in mice resembling KS, and antisense oligonucleotides against this cytokine inhibit the growth and angiogenic activity of KS spindle cells. 330
The angiogenic properties of HIV-I Tat protein are mediated by two different domains. 327
[Chronic T-lymphocyte lymphatic leukemia. Clinico-pathologic assessment and new epidemiologic data related to cases correlated with HTLV-I in Italy] 320
Effects of cytokines from activated immune cells on vascular cell growth and HIV-1 gene expression. Implications for AIDS-Kaposi's sarcoma pathogenesis 318
T-helper phenotype chronic lymphocytic leukaemia and "adult T-cell leukaemia" in Italy. Endemic HTLV-I-related T-cell leukaemias in southern Europe 318
Effects of the human immunodeficiency virus type 1 Tat protein on the expression of inflammatory cytokines 318
Role of cytokines from activated T cells and HIV-1 Tat protein in the pathogenesis of AIDS-associated Kaposi’s sarcoma. 318
The Tat protein of human immunodeficiency virus type-1 promotes vascular cell growth and locomotion by engaging the alpha5beta1 and alphavbeta3 integrins and by mobilizing sequestered basic fibroblast growth factor 317
Release-uptake of HIV-1 Tat and mechanisms of Tat-induced paracrine biological effects. 314
Cytokines released by activated primary T cells stimulate the growth of AIDS-KS-derived cells and other cells of mesenchymal derivation. 311
[HIV protease inhibitors for the treatment of Kaposi's sarcoma] 308
Immune stimulation and HIV-1 infection have complementary effects in the induction and progression of AIDS-associated Kaposi’s sarcoma via release of cytokines and Tat. 304
HIV-1 Tat protein enhances angiogenesis and Kaposi’s sarcoma development triggered by inflammatory cytokines or bFGF by engaging the avb3 integrin. 302
Cooperation of HIV-1 Tat protein, inflammatory cytokines or bFGF in the pathogenesis of AIDS-Kaposis’s sarcoma. 296
Inflammatory cytokines increase mesenchymal cell growth and attachment induced by HIV-1 Tat protein and adhesion molecules: implications for AIDS-Kaposi’s sarcoma pathogenesis. 286
Activated peripheral blood lymphocytes produce factors promoting the growth of spindle cells derived from AIDS-associated Kaposi’s sarcoma. 265
About a Possible Impact of Endodontic Infections by Fusobacterium nucleatum or Porphyromonas gingivalis on Oral Carcinogenesis: A Literature Overview 218
Combined treatment with inhibitors of ErbB Receptors and Hh signaling pathways is more effective than single treatment in reducing the growth of malignant mesothelioma both in vitro and in vivo 205
Proteasome inhibition by bortezomib parallels a reduction in head and neck cancer cells growth, and an increase in tumor-infiltrating immune cells 197
DNAM-1 chimeric receptor-engineered NK cells: a new frontier for CAR-NK cell-based immunotherapy 193
Antitumoral effects of Bortezomib in malignant mesothelioma: evidence of mild endoplasmic reticulum stress in vitro and activation of T cell response in vivo 187
Infection by high-risk human papillomaviruses, epithelial-to-mesenchymal transition and squamous pre-malignant or malignant lesions of the uterine cervix: a series of chained events? 163
Correlation between pathological data and the RNA expression of p53 or p53-targeted genes in primary invasive ductal breast carcinomas: a preliminary study 150
Dietary Polyphenols Effects on Focal Adhesion Plaques and Metalloproteinases in Cancer Invasiveness 143
Radioresistance in rhabdomyosarcomas: much more than a question of dose 131
Biomarkers Identification in the Microenvironment of Oral Squamous Cell Carcinoma: A Systematic Review of Proteomic Studies 130
Combined mitoxantrone and anti-TGFβ treatment with PD-1 blockade enhances antitumor immunity by remodelling the tumor immune landscape in neuroblastoma 124
Spermine oxidase induces DNA damage and sensitizes fusion negative rhabdomyosarcoma cells to irradiation 120
DNA Damage Response Gene Signature as Potential Treatment Markers for Oral Squamous Cell Carcinoma 119
Totale 35.812
Salva come PNG Salva come JPEG
Categoria #
all - tutte 85.719
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 85.719
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022757 0 0 0 63 18 43 48 119 32 54 85 295
2022/20231.326 159 110 100 143 97 276 113 80 123 43 68 14
2023/2024458 49 13 23 17 38 159 20 12 10 38 17 62
2024/20252.777 91 675 324 136 52 143 136 126 225 298 422 149
2025/20264.523 272 155 492 248 390 113 503 474 544 335 828 169
2026/20271.732 160 184 958 430 0 0 0 0 0 0 0 0
Totale 37.373